305 results on '"Sugawara, Kazunobu"'
Search Results
2. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma
3. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations
4. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve
5. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes
6. A developed determination of midazolam and 1′-hydroxymidazolam in plasma by liquid chromatography–mass spectrometry: Application of human pharmacokinetic study for measurement of CYP3A activity
7. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes
8. Determination of Estazolam in Plasma by High-Performance Liquid Chromatography with Solid-Phase Extraction
9. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: Application to pharmacokinetic study in relation to CYP2C19 genotypes
10. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam
11. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
12. Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study
13. Determination of lansoprazole and two of its metabolites by liquid–liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity
14. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
15. Determination of Alprazolam and α-Hydroxyalprazolam in Plasma by High-Performance Liquid Chromatography
16. The Role of Cytochrome P2C19 in R-warfarin Pharmacokinetics and its Interaction With Omeprazole
17. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
18. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects
19. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
20. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
21. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine
22. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes
23. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
24. Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes
25. Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection
26. Fexofenadine does Not Affect Omeprazole Pharmacokinetics: Both are putative P-Glycoprotein Substrates
27. Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam
28. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin
29. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment
30. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients
31. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype
32. Metabolic Disposition of Pantoprazole in Japanese Subjects: Relation to S-Mephenytoin Phenotype: PIV-3
33. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism
34. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia
35. Evaluation of Influence of Mothers' Medications Upon Breast-fed Infants
36. Simultaneous Determination of Warfarin Enantiomers and Its Metabolite in Human Plasma by Column-Switching High-Performance Liquid Chromatography With Chiral Separation
37. Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine
38. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma
39. Sensitive Determination of Itraconazole and Its Active Metabolite in Human Plasma by Column-switching High-performance Liquid Chromatography With Ultraviolet Detection
40. Identification of a Single Time-point for Plasma Lansoprazole Measurement That Adequately Reflects Area Under the Concentration-Time Curve
41. Microbial Contamination of Enteral Nutrient Solutions and Way of Preventing it
42. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes
43. Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam
44. Proper Use of ETHACOTT Commercial Alcohol-impregnated Cotton Swabs-Examination of Sterilization Effect Using Bacteria Isolated in Clinical Practice-
45. Effects of Sucralfate, Magnesium Oxide and Sodium Ferrous Citrate on Sparfloxacin Pharmacokinetics.
46. Monoamine oxidase-A gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder
47. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder
48. Relationship Between Plasma Concentrations of Trazodone and Its Active Metabolite, m-Chlorophenylpiperazine, and Its Clinical Effect in Depressed Patients
49. Graphic roots of CYP2C19 genetic polymorphism in Japanese population (preliminary report)
50. No Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Estazolam
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.